During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase ...

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple ...

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients ...

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical ...

In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the ...

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma ...

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in ...